首页> 美国卫生研究院文献>Arrhythmia Electrophysiology Review >Pharmacological Therapy of Tachyarrhythmias During Pregnancy
【2h】

Pharmacological Therapy of Tachyarrhythmias During Pregnancy

机译:妊娠期快速性心律失常的药理治疗

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Tachyarrhythmias are the most frequently observed cardiac complications during pregnancy. The majority of these maternal and foetal arrhythmias are supraventricular tachyarrhythmias; ventricular tachyarrhythmias are rare. The use of anti-arrhythmic drugs (AADs) during pregnancy is challenging due to potential foetal teratogenic effects. Maintaining stable and effective therapeutic maternal drug levels is difficult due to haemodynamic and metabolic alterations. Pharmacological treatment of tachyarrhythmias is indicated in case of maternal haemodynamic instability or hydrops fetalis. Evidenc e regarding the efficacy and safety of AAD therapy during pregnancy is scarce and the choice of AAD should be based on individual risk assessments for both mother and foetus. This review outlines the current knowledge on the development of tachyarrhythmias during pregnancy, the indications for and considerations of pharmacological treatment and its potential side-effects.
机译:快速性心律失常是怀孕期间最常见的心脏并发症。这些产妇和胎儿心律不齐的大多数是室上性心律失常。室性心律失常是罕见的。由于潜在的胎儿致畸作用,怀孕期间使用抗心律不齐药物(AADs)具有挑战性。由于血液动力学和代谢改变,难以维持稳定和有效的治疗性母体药物水平。如果孕妇血流动力学不稳定或胎儿积水,则应进行药物性快速性心律失常的药理治疗。关于怀孕期间AAD治疗的有效性和安全性的证据很少,因此应根据对母亲和胎儿的个体风险评估来选择AAD。这篇综述概述了妊娠期快速性心律失常的发展的当前知识,药物治疗的适应症和考虑因素及其潜在的副作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号